Improved QC for upstream and downstream cell and gene therapy manufacturing

Thanks to the improved analytical QC of TLA, we have witnessed a surge in the adoption of our proprietary technology in the field of cell and gene therapy. Some of our collaborative works, with both leading academic institutes and larger pharmaceutical companies, have culminated in publications, some of which are presented here during this session.

In this webinar, recorded March 18 2020, we discussed about:

  • Principles of TLA
  • Applications of TLA in cell and gene therapy manufacturing
  • Complete characterization of producer cell lines
  • Assessment of downstream heterogeneous cell and gene therapy products
  • TLA-based clone selection, clonality and genetic stability assessment


For an overview of the publications cited in the presentation, click here

Please contact us for more information.



© 2012-2021 Cergentis B.V. All rights reserved.
For Research Use Only.Not for use in diagnostic procedures.
We use cookies for website analysis and marketing. By visiting and using our website you accept these cookies.